Navigation Links
Mystery solved: Facial cancer decimating Tasmanian devils likely began in Schwann cells
Date:12/31/2009

Cold Spring Harbor, N.Y. An international team of scientists led by a Cold Spring Harbor Laboratory (CSHL) investigator has discovered that the deadly facial tumors decimating Australia's Tasmanian devil population probably originated in Schwann cells, a type of tissue that cushions and protects nerve fibers.

The discovery stems from the team's effort to carry out a genetic analysis of tumor cells. Based on these data, the scientists have identified a genetic marker to accurately diagnose the facial cancers, called devil facial tumor disease (DFTD).

The findings, which open new avenues for research into treatments and vaccines, will appear in the journal Science on January 1. Elizabeth Murchison, Ph.D., of CSHL and the Australian National University, is lead author of the paper; the work was conducted with CSHL Professor and HHMI Investigator Greg Hannon, Ph.D., among others.

DFTD is a unique type of cancer that is transmitted from animal to animal via biting or other physical contact one of only two cancers known to spread by this method, which transfers living cancer cells between individuals (the other cancer is found in dogs). The devils' tumors are mostly found on the face and mouth, but often spread to internal organs. With no diagnostic tests, treatments or vaccines currently available, this aggressive disease could wipe out the Tasmanian devil species in 25 to 35 years.

"Our findings represent a big step forward in the race to save the devils from extinction," says Murchison. The research has provided a method for scientists to distinguish between DFTD and other types of devil cancers. This could be critical in efforts to identify and isolate affected animals and contain the disease's spread.

The team's genetic analysis has confirmed that the tumors that spread from animal to animal are genetically identical exact clonal copies, each having originated from a single line of cells. The team determined the identity of the originating cell by using advanced sequencing technology to uncover the tumors' "transcriptome" the complete set of genes that are turned on in tumor cells. Comparing this readout to that from other tissues, the team found that the tumors' genetic signature best matched that of Schwann cells. How these nervous system cells spawned cancer is still a mystery.

"Now that we've taken a good look at the tumors' genetic profile, we can start hunting for genes and pathways involved in tumor formation," says Hannon. The team has also compiled a catalogue of devil genes that might influence the pathology and transmission of the tumor -- information that will be very useful in designing vaccines and other therapeutic strategies.


'/>"/>

Contact: Hema Bashyam
bashyam@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology news :

1. Mystery of golden ratio explained
2. Scripps Research scientists crack mystery of proteins dual function
3. Introns: A mystery renewed
4. Scientists are first to unlock the mystery of creating cultured pearls from the queen conch
5. Mystery solved: Marine microbe is source of rare nutrient
6. Baylor researchers unravel mystery of DNA conformation
7. Mystery E. coli genes essential for survival of many species
8. Mystery of bat with an extraordinary nose solved
9. Harvard scientists solve mystery about why HIV patients are more susceptible to TB infection
10. Scientists tackle the mystery of white-nose syndrome in bats
11. Scientists unravel the mystery of white-nose syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/18/2017)... ... 18, 2017 , ... Opal Kelly, a leading producer of ... announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface ... factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total ... successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, ... The procedure was an anterior cervical discectomy and fusion on a 42 year ...
Breaking Biology Technology: